ReviewMethods in molecular biology (Clifton, N.J.)2025
Cerebrospinal Fluid Metabolomics and Proteomics Integration in Neurological Syndromes.
Review in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebrospinal Fluid Biomarkers in Creutzfeldt-Jakob Disease: Diagnostic Value, Limitations, and Future Multi-Omics Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of multi-omics data has increasingly been recognized as an effective approach to addressing complex problems and advancing precision medicine. Metabolomics and proteomics are closely related, and their integration provides complementary insights and enables cross-validation of experimental results. The integration of proteomics and metabolomics in cerebrospinal fluid is expected to reconstruct the complex biological networks underlying nervous system diseases, enhance understanding of molecular mechanisms, and aid in disease classification and prognosis prediction. However, integrating multi-omics data still faces numerous challenges, limiting the application of combined proteomic and metabolomic analyses in neurological diseases. Based on the advantages of integrated proteomics and metabolomics, this chapter introduces, for the first time, common strategies for the integrated analyses of omics data. Furthermore, we review advances in cerebrospinal fluid proteomics and metabolomics for neurological syndromes, highlighting current challenges and future directions.
Indexed as
Identifiers
40167926What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.